ArticleFrontiers in oncology2025
Real-world analysis of community colorectal neoplasia screening based on stool DNA methylation detection.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the effectiveness of stool DNA methylation detection (sDNAMD) in improving colorectal neoplasia (CN) detection rates and colonoscopy compliance in a real-world community setting. Between July 1, 2023, and June 30, 2024, residents aged 50-75 from Maqiao Town, Minhang District, Shanghai, were invited to participate in a CN screening program. Participants were randomly assigned to one of three groups: high-risk questionnaire + fecal occult blood test (HRFO), high-risk questionnaire + FOBT + sDNAMD (HRFOsD), or sDNAMD only (sDNA). Colonoscopy was performed based on initial screening results, and the number of individuals undergoing colonoscopy, along with results, were recorded to calculate compliance and CN detection rates. The HRFOsD group exhibited a significantly higher colonoscopy compliance rate (93.7%) compared to the HRFO (32.6%) and sDNA (73.5%) groups (P<0.0001). Residents with negative FOBT, negative sDNA results, or those who did not undergo sDNA testing did not undergo colonoscopy. In the HRFOsD group, the CN detection rate was higher in females compared to males. Compared to the HR and FOBT+ group, the CN detection rate was significantly higher in the LR and FOBT+ and sDNA+ group. Adding sDNAMD to the high-risk questionnaire and FOBT screening led to a notable increase in both colonoscopy compliance and CN detection rates. The conclusion is that adding stool DNA methylation detection to the community FOBT screening program can significantly improve colonoscopy compliance and colorectal neoplasia detection rates among community residents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.